Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$0.00
$0.14
$0.16
$1.57
$6K4.024,068 shs78 shs
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
$0.00
$0.18
$0.00
$3.40
$31K-17.745,371 shsN/A
Regenicin, Inc. stock logo
RGIN
Regenicin
$0.00
+∞
$0.00
$0.00
$0.00
$17K-18.9117,300 shs75,000 shs
VRAYQ
ViewRay
$0.00
$0.00
$0.00
$18K1.02616 shsN/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00%0.00%+33.33%-99.48%-99.89%
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
0.00%-99.85%-99.85%-99.77%-99.85%
Regenicin, Inc. stock logo
RGIN
Regenicin
0.00%0.00%0.00%0.00%-98.00%
VRAYQ
ViewRay
0.00%0.00%0.00%+3.00%+3.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
N/AN/AN/AN/AN/AN/AN/AN/A
Regenicin, Inc. stock logo
RGIN
Regenicin
N/AN/AN/AN/AN/AN/AN/AN/A
VRAYQ
ViewRay
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
0.00
N/AN/AN/A
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
0.00
N/AN/AN/A
Regenicin, Inc. stock logo
RGIN
Regenicin
0.00
N/AN/AN/A
VRAYQ
ViewRay
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
$80K0.07N/AN/A($2.43) per share0.00
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
$80K0.39N/AN/A$0.38 per share0.00
Regenicin, Inc. stock logo
RGIN
Regenicin
N/AN/AN/AN/AN/AN/A
VRAYQ
ViewRay
$102.21M0.00N/AN/AN/ANaN
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
-$6.98MN/A0.00N/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
-$270KN/A0.00N/A-453.55%-6.43%-4.43%N/A
Regenicin, Inc. stock logo
RGIN
Regenicin
-$640KN/A0.00N/AN/AN/AN/AN/A
VRAYQ
ViewRay
-$107.33MN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/AN/AN/AN/AN/A
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
N/AN/AN/AN/AN/A
Regenicin, Inc. stock logo
RGIN
Regenicin
N/AN/AN/AN/AN/A
VRAYQ
ViewRay
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
N/A
0.10
0.01
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
N/A
0.35
0.34
Regenicin, Inc. stock logo
RGIN
Regenicin
N/AN/AN/A
VRAYQ
ViewRay
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
6.91%
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
N/A
Regenicin, Inc. stock logo
RGIN
Regenicin
0.01%
VRAYQ
ViewRay
15.47%

Insider Ownership

CompanyInsider Ownership
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
4.50%
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
89.24%
Regenicin, Inc. stock logo
RGIN
Regenicin
N/A
VRAYQ
ViewRay
2.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arch Therapeutics, Inc. stock logo
ARTH
Arch Therapeutics
104.74 million4.53 millionNot Optionable
Heyu Biological Technology Co. stock logo
HYBT
Heyu Biological Technology
6103.25 million11.11 millionNot Optionable
Regenicin, Inc. stock logo
RGIN
Regenicin
3165.77 millionN/ANot Optionable
VRAYQ
ViewRay
300183.40 million178.82 millionNo Data

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Top Headlines

View All Headlines
Arch Therapeutics stock logo

Arch Therapeutics OTCMKTS:ARTH

$0.0012 0.00 (0.00%)
As of 06/16/2025

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.

Heyu Biological Technology stock logo

Heyu Biological Technology OTCMKTS:HYBT

$0.0003 0.00 (0.00%)
As of 06/16/2025

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.

Regenicin stock logo

Regenicin OTCMKTS:RGIN

$0.0001 +0.00 (+∞)
As of 05:20 PM Eastern

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

ViewRay NASDAQ:VRAYQ

ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay , Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.